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Abstract
Background: It is unclear whether estrogen receptor (ER)-status of first primary breast cancer is associated with risk of
metachronous (non-simultaneous) contralateral breast cancer (CBC), and to what extent endocrine therapy affects this
association.
Methods: We studied the effect of ER-status of the first cancer on the risk of CBC overall, and for different ER-subtypes of
CBC, using a large, population-based cohort. The cohort consisted of all women diagnosed with breast cancer in the
Stockholm region 1976–2005; 25715 patients, of whom 940 suffered CBC. The relative risk was analyzed mainly using
standardized incidence ratios (SIR).
Results: Women with breast cancer had a doubled risk of CBC compared to the risk of breast cancer in the general female
population (SIR: 2.22 [2.08–2.36]), for women with a previous ER-positive cancer: SIR = 2.30 (95% CI:2.11–2.50) and for
women with a previous ER-negative cancer: SIR = 2.17 (95% CI:1.82–2.55). The relative risk of ER-positive and ER-negative
CBC was very similar for women with ER-positive first cancer (SIR = 2.02 [95%CI: 1.80–2.27] and SIR = 1.89 [95%CI: 1.46–2.41]
respectively) while for patients with ER-negative first cancer the relative risk was significantly different (SIR = 1.27 [95%
CI:0.94–1.68] for ER-positive CBC and SIR = 4.96 [95%CI:3.67–6.56] for ER-negative CBC). Patients with ER-positive first cancer
who received hormone therapy still had a significantly higher risk of CBC than the risk of breast cancer for the general
female population (SIR = 1.74 [95% CI:1.47–2.03]).
Conclusion: The risk of CBC for a breast cancer patient is increased to about two-fold, compared to the risk of breast cancer
in the general female population. This excess risk decreases, but does not disappear, with adjuvant endocrine therapy.
Patients with ER-positive first cancers have an increased risk for CBC of both ER subtypes, while patients with ER-negative
first cancer have a specifically increased risk of ER-negative CBC.
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Introduction
Of all women with breast cancer, each year 0.6–0.7% will
develop contralateral breast cancer (CBC) [1,2,3,4,5,6], translating
into approximately 10–15% of all breast cancer patients being
diagnosed with CBC during the first 20 years after initial diagnosis
[4,7]. The risk of CBC does not seem to decline with time since
first diagnosis [5,8], it is however higher for patients that were
young at their first breast cancer [9,10,11]. Further, CBC-patients
have a considerably worse prognosis than patients with unilateral
breast cancer, as the authors of this paper have shown previously
[12].
Estrogen receptor (ER) status acts both as a prognosticator,
independent of treatment, but also as a predictor of endocrine
therapy response [13,14,15]. It is still not clear how hormone
receptor status of the first breast cancer affects the risk of CBC.
Several studies show that, among breast cancer patients there is no
effect of ER-status of the first cancer on the risk of CBC-
[16,17,18,19,20]. This is however not uncontroversial; two studies
show that breast cancer patients with positive ER-status have
lower risk of CBC compared to patients with ER-negative first
breast cancer [21,22]. Though it should be noted that neither of
these two studies had the opportunity to account for endocrine
therapy, one of the studies found this association to be effect
modified by age at diagnosis and only apparent for young women
[22]. Randomized trials have shown that adjuvant endocrine
therapy decreases the risk of CBC overall [9], but there have been
indications that endocrine therapy might increase the risk of ER-
negative CBC substantially [23]. Many of the previous studies on
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this subject [16,17,18,19,20,22] have been limited by small sample
size (number of CBC cases ranging from 43 to 131) and/or have
focused on only one aspect (i.e. only ER-status or only endocrine
therapy) in the interplay between risk, ER-status of the two tumors
and the treatment given. This study, on the other hand, aims at a
comprehensive analysis of the relationship between ER-status of
the first tumor, endocrine therapy and ER-status of the second
tumor and has a sufficient sample size (N= 695) to confidently
answer these questions. We conducted a population-based
analysis, contrasting the risk to develop CBC among breast cancer




This study was approved by the ethical committee at the
Karolinska Institutet, Stockholm, Sweden. As the study was purely
register based, no contact was made with the study persons and the
data were analyzed anonymously informed consent was not
obtained. The exception from informed consent was confirmed by
the ethical committee.
Study population
The Stockholm Breast Cancer Register is a population-based
register to which all breast cancer patients in the Stockholm-
Gotland health-care region of Sweden are reported. The register is
complete from 1976 and contains, among other clinical variables,
date of birth, date of diagnosis, ER-status and information on
subsequent cancers, distant metastasis and date of death. Adjuvant
therapy is included in the register from 1990. In this study we
included all women who were recorded in the Stockholm Breast
Cancer Register during 1976–2005 as having invasive breast
cancer occurring as the patient’s first malignancy and not
diagnosed in TNM-stage 4 (N= 25 715). We investigated the risk
of CBC, defined as invasive contralateral breast cancer occurring
as the patient’s second malignancy and not diagnosed in TNM-
stage 4. By these restrictions we tried to ensure that the breast
cancers were primary malignancies, and not misclassified meta-
static events.
Further, women with CBC that occurred less than 3 months
after the first breast cancer could not be part of the study
population, since we regard their two cancers as simultaneous.
The cutoff of 3 months for simultaneous CBC has been used
previously by our group and others [24,25,26]. Consequently,
while the population at risk of CBC is breast cancer patients, the
population at risk for simultaneous CBC is breast-cancer free
women, i.e. the general female population. Furthermore, in our
risk calculations we differentiate between the first and second
cancer, which is not possible among simultaneously occurring
CBCs.
The measurement of ER-status during the study period is
naturally of crucial importance for this study. Prior to 1988
isoelectric focusing [27] was used to assess ER-status, from 1988–
2003 an ELISA assay (Abbott Laboratories kit) [28] was used, and
during the two last years of this study immunohistochemistry
(DAKO Laboratories kit) was used. The measurements from these
methods have been shown to be highly correlated [29,30] and also
to correlate well with more recent methods, like RT-PCR [31].
The ELISA assay measured fmole/mg DNA and any tumor with a
concentration of ER $0.05 fmol/mg DNA was defined as ER-
positive, tumors measured with the immunohistochemistry meth-
od were classified as positive if 10% or more of the tumor cells
expressed ER.
For the analysis of endocrine therapy we restricted our cohort to
patients with their first cancer diagnosed after 1990 (approxi-
mately 60% of the cohort), since treatment information was not
included in the register until then. Endocrine treatment was
recorded as yes/no, and for one third of the patients the type of
endocrine therapy was also specified. (Tamoxifen for 75% of the
patients and aromatase inhibitors for 22%.)
Statistical analysis
Incidence of CBC was estimated as the number of cases divided
by total person time (person-years) at risk, from first diagnosis of
breast cancer until date of CBC or censoring (date of malignancy
at any other site, date of distant metastasis, date of death or
December, 31, 2005, whichever came first). The cumulative
incidence of CBC was estimated by the Nelson-Aalen estimator
[32] and is shown graphically for CBC overall, ER-positive CBC
and ER-negative CBC, by ER-status of the first cancer. The log-
rank test with 5% significance level was used to assess whether the
cumulative incidence differed between patients with ER-positive
and ER-negative first cancer.
We used the standardized incidence ratio (SIR) to investigate
the risk of CBC among breast cancer patients, compared to the
risk of unilateral breast cancer in the general (breast-cancer free)
female population. We calculated the ratio of observed to expected
number of CBC-cases, in 5-year age intervals and 5-year calendar-
period intervals. The background rate used for calculating the
expected number of CBCs was the 5-year-age- and 5-year-period-
specific rate of breast cancer in Stockholm during the study period
(1976–2005), which we calculated from population counts of the
general population of women and number of unilateral breast
cancer patients in the Stockholm Breast Cancer Register. We
calculated the rates separately for all breast cancer, for ER-positive
cancer and for ER-negative cancer, thereby enabling us to
compare the rate of e.g. ER-negative CBC to the rate of ER-
negative unilateral breast cancer. We used 95% confidence
intervals (CI) based on the Poisson distribution for the SIR to
determine statistical significance [33].
As a sensitivity analysis we also calculated the SIRs restricted to
patients with known ER-status (also of the second cancer, if
present), with the aim of investigating the potential effect of
missingness of ER-status. Further, we investigated whether the risk
of CBC, as compared to the risk of breast cancer in the general
population, differed depending on how long time had passed since
the first breast cancer. In effect, the observed over expected ratio
of CBC during the first five years from diagnosis of primary cancer
was calculated, by counting the accumulated person time (which,
by using the background rate for the general population, gave rise
to the expected number of CBCs) and observed number of CBCs,
during these first five years. Then, the number of observed CBCs
occurring more than 5 years after the first breast cancer and the
person time accumulated from the time point five years after first
primary diagnosis and until the end of follow up was calculated,
giving rise to an observed over expected ratio in this group. These
two ratios could then be compared and whether they differ will
answer the question of whether the risk of CBC, as compared to
the risk of breast cancer in the general population, differ by time
since the first breast cancer.
All data preparation and analyses were done using SAS
Statistical Package 9.2.
Results
The final cohort consisted of 25 715 breast cancer patients, of
which 18 853 (73%) had known ER-status; 14 720 had ER-
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positive breast cancer and 4 133 had ER-negative cancer (Table 1).
Among these 25 715 women 940 contralateral breast cancers were
diagnosed; 553 with ER-positive first cancer, 142 with ER-
negative and 245 with unknown ER-status at first cancer. The
mean age at (first) breast cancer diagnosis was 61.1 years (range:
18–101) and the mean age at CBC was 63.6 years (range 23–90).
The overall incidence of CBC was 454 cases per 100 000 person-
years (PYR), the specific incidence of ER-positive and ER-negative
CBC was 219 and 78 per 100 000 PYR, respectively. The overall
5-year incidence decreased from 533 cases per 100 000 PYR, for
women diagnosed with their first cancer in 1976–1980 to 322
cases per 100 000 PYR for women diagnosed with their first
cancer in 1996–2000. Among the patients diagnosed with (first)
breast cancer after 1990 (N= 15 145) 69% received endocrine
therapy, 24% received no endocrine therapy and endocrine
therapy was unknown for 7% of the patients. 349 CBC-cases arose
in this restricted cohort.
The cumulative incidence of CBC given the ER-status of the
first cancer is shown by Nelson-Aalen plots in Figure 1. The
incidence of CBC overall is given in panel A and panel B shows
the incidence of ER-positive and ER-negative CBC by ER-status
of the first cancer. The cumulative incidence of CBC overall was
not statistically different depending on ER-status for the first
cancer (P = 0.338), but the cumulative incidence of ER-positive
CBC was statistically significantly higher for patients with ER-
positive first cancer, compared to patients with ER-negative first
cancer (P,0.001), and likewise was the cumulative incidence of
ER-negative CBC statistically significantly higher for patients with
ER-negative first cancer, compared to patients with ER-positive
first cancer (P,0.001). These analyses was based only on the
patients for which ER-status (also of the second cancer, if present)
is known (N= 18 615). This cohort was used also in panel A,
where information of ER-status of the second cancer is not strictly
needed, to enable comparison between the panels.
The risk for breast cancer patients to develop CBC was 2.22
times higher (95% CI: 2.08–2.36) than the risk of the general
female population to develop unilateral breast cancer (Table 2).
Further, we found a SIR of 2.30 (95% CI: 2.11–2.50) when
separately investigating the risk of CBC among patients with ER-
positive first breast cancer, the corresponding relative risk among
patients with ER-negative first cancer was 2.17 (95% CI: 1.82–
2.55). Overall, the relative risk of CBC is significantly higher for
the younger patients (i.e. women diagnosed with their first breast
cancer before the age of 50), the risk is two to three-fold higher
than for patients diagnosed with their first cancer at/after the age
of 50 (Table 2). When investigating the SIRs closer (,5 years) and
further (.5 years) from first diagnosis we did not find any evidence
of a difference between these two relative risks (data not shown).
As a sensitivity analysis we restricted our cohort to only the
patients for which ER-status (also of the second cancer, if present)
was known (N= 18 615), the purpose was to investigate the effect
of missingness of ER-status on our estimates. We calculated the
risk for breast cancer patients to develop CBC compared to the
risk of the general female population to develop unilateral breast
cancer; SIR=2.02 (95% CI= 1.84–2.21, N=457). The relative
risk among women with ER-positive first cancer was 2.02 (95%
CI= 1.81–2.24, N= 358) and among women with ER-negative
first cancer 2.03 (95% CI= 1.65–2.47, N=99). These findings are
thus in concordance with the risk estimates for the full cohort
(Table 2). In addition, we also conducted a sensitivity analysis of
the definition of non-simultaneous CBC; using a cutoff of one year
between the first and second cancer, instead of three months. The
results were however very similar (see supplementary online
material, Table S1).
When investigating the relative risk of ER-positive and ER-
negative CBC separately (Table 3) we found that the risk of CBC
compared to unilateral breast cancer is statistically significantly
increased in all ER-subgroups except for ER-positive CBC among
the patients with ER-negative first cancer. Further, we found no
significant difference between the relative risk of ER-positive and
ER-negative CBC for patients with ER-positive first cancer
(SIR= 2.02 [95%CI: 1.80–2.27] and SIR=1.89 [95%CI: 1.46–
2.41] respectively). In contrast, for patients with ER-negative first
cancer the risk was notably and statistically significantly different;
patients with ER-negative first cancer had no increased risk of ER-
positive CBC (SIR= 1.27 [95% CI: 0.94–1.68]) but an almost five-
fold increased risk for ER-negative CBC (SIR=4.96 [95%CI:
3.67–6.56]). The risks for both ER-positive and ER-negative CBC
was further increased among women younger than 50 years at first
diagnosis, most notably for ER-negative CBC (Table 3).
We evaluated the effect of endocrine therapy for the first cancer
for women with ER-positive breast cancer by calculating the SIRs
for the patients for whom we had information on endocrine
therapy (patients diagnosed from 1990). The overall relative risk of
CBC, as well as the risk of ER-positive CBC, was lower for the
Table 1. Characteristics of the unilateral breast cancer cohort
and the CBC-cohort; 1976–2005 in the Stockholm-Gotland
region.
Breast cancer* CBC
No of patients 25 715 940
Age at (first) diagnosis
,45 3059 (12%) 152 (16%)
45–55 5728 (22%) 275 (29%)
55–65 6445 (25%) 244 (26%)
65–75 5606 (22%) 202 (21%)
.75 4877 (19%) 67 (7%)
Calendar period of (first) diagnosis
1976–1985 6426 (25%) 375 (40%)
1985–1995 8900 (35%) 430 (46%)
1995–2005 10 389 (40%) 135 (14%)
Time between first and second cancer
Mean years (std dev) - 6.9 (5.4)
Estrogen receptor status:
Positive at first cancer 14 720 (57%) 553 (59%)
Positive at second cancer 292 (31%)
Negative at second cancer 66 (8%)
Unknown at second cancer 195 (21%)
Negative at first cancer 4133 (16%) 142 (15%)
Positive at second cancer 50 (5%)
Negative at second cancer 49 (3%)
Unknown at second cancer 43 (5%)
Unknown at first cancer 6862 (27%) 245 (26%)
Positive at second cancer 111 (12%)
Negative at second cancer 46 (5%)
Unknown at second cancer 88 (9%)
*This cohort is the study population for this study, it includes all breast cancer
patients, both those that will develop CBC and those that will not.
CBC = contralateral breast cancer. Std dev = standard deviation.
doi:10.1371/journal.pone.0046535.t001
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Figure 1. Nelson –Aalen plots. Cumulative incidence of CBC for women with ER-negative vs. ER-positive first breast cancer. Panel A shows the
cumulative incidence of CBC of any ER-subtype by ER-status of the first cancer. The p-value for the log-rank test of cumulative incidence of CBC
overall was 0.338, thus the cumulative incidence of CBC did not differ between patients with ER-positive vs. ER-negative first primary breast cancer.
Panel B shows the cumulative incidence of ER-positive and ER-negative CBC by ER-status of the first cancer. (The p-value for the log-rank test of
cumulative incidence of ER-positive CBC show significant difference between patients with ER-positive vs. ER-negative first breast cancer (P-
value =,0.001) and similarly the p-value for the log-rank test of cumulative incidence of ER-negative CBC also show significant difference between
patients with ER-positive vs. ER-negative first breast cancer (P-value=,0.001). See Table 5 for number of women at risk.
doi:10.1371/journal.pone.0046535.g001
Estrogen Receptors in Contralateral Breast Cancer
PLOS ONE | www.plosone.org 4 October 2012 | Volume 7 | Issue 10 | e46535
endocrine-therapy treated women (SIR for CBC overall = 1.74
(95% [CI: 1.47–2.03]), compared to non-endocrine treated (SIR
for CBC overall = 2.81 [95% CI: 1.98–3.87]), while no corre-
sponding risk reduction was found for ER-negative CBC (Table 4).
Discussion
We found the risk of CBC for breast cancer patients to be about
twice as high compared to the risk of breast cancer in the general
(breast-cancer free) female population, independently of ER-status
of the first cancer. However, while ER-positive breast cancer
seems to predict an increased risk for CBC in general, an ER-
negative first cancer seems to specifically increase the risk for ER-
negative CBC, and not for ER-positive CBC. The risk of CBC is
highly increased for all women with first breast cancer diagnosed
before the age of 50, and we now show that this increase is more
pronounced for ER-negative CBC. Endocrine therapy for the first
cancer decreases the risk of CBC, compared to when no endocrine
therapy is given, this decrease was mediated through the risk of
Table 2. Standardized incidence ratios (SIR) comparing the incidence of CBC to the incidence of unilateral breast cancer, overall
and according to ER-status of the first breast cancer, for all patients and stratified on age.
Risk of CBC
Women at risk N
Person years at
risk Observed cases N SIR 95% CI
Overall
All first breast cancer 24 775 192 247 940 2.22 2.08–2.36
ER-positive first breast cancer 14 167 108 298 553 2.30 2.11–2.50
ER-negative first breast cancers 3 991 30 573 142 2.17 1.82–2.55
Patients diagnosed before age of 50
All first breast cancer 5 357 23 927 152 5.73 4.86–6.72
ER-positive first breast cancer 2 822 11 783 79 5.87 4.64–7.31
ER-negative first breast cancers 1 190 5 397 29 5.15 3.45–7.40
Patients diagnosed at/after age of 50
All first breast cancer 19 418 168 320 788 1.98 1.85–2.13
ER-positive first breast cancer 11 345 96 515 474 2.08 1.90–2.28
ER-negative first breast cancers 2 801 25 176 113 1.89 1.55–2.26
26% of the CBC-cases had unknown ER-status at their first cancer, 34% of the CBC-cases had unknown ER-status of their second cancer.
SIRs standardized for age at diagnosis in 5-year-categories and for period of diagnosis in 5-year-categories.
SIR = Standardized incidence ratio, CI = Confidence Interval, CBC = contralateral breast cancer, ER = Estrogen receptor.
doi:10.1371/journal.pone.0046535.t002
Table 3. Standardized incidence ratios (SIR) comparing the incidence of ER-positive and ER-negative CBC to the incidence of
unilateral breast cancer, overall and according to ER-status of the first breast cancer, for all patients and stratified on age.
Risk of ER-positive CBC Risk of ER-negative CBC P-value of Wald test
Observed cases N SIR 95% CI Observed cases N SIR 95% CI
Overall
All first breast cancer 453 1.78 1.62–1.96 161 2.60 2.21–3.03 ,0.01
ER-positive first breast cancer 292 2.02 1.80–2.27 66 1.89 1.46–2.41 0.63
ER-negative first breast cancers 50 1.27 0.94–1.68 49 4.96 3.67–6.56 ,0.01
Patients diagnosed before age of 50
All first breast cancer 54 3.61 2.71–4.71 37 7.02 5.94–9.67 ,0.01
ER-positive first breast cancer 38 4.97 3.52–6.81 8 3.00 1.29–5-91 0.19
ER-negative first breast cancers 5 1.58 0.51–3.70 15 13.20 7.39–21.77 ,0.01
Patients diagnosed at/after age of 50
All first breast cancer 399 1.66 1.51–1.84 124 2.19 1.82–2.61 ,0.01
ER-positive first breast cancer 254 1.86 1.64–2.10 58 1.80 1.37–2.33 0.82
ER-negative first breast cancers 45 1.25 0.91–1.67 34 3.89 2.69–5.44 ,0.01
26% of the CBC-cases had unknown ER-status at their first cancer, 34% of the CBC-cases had unknown ER-status of their second cancer.
SIRs standardized for age at diagnosis in 5-year-categories and for period diagnosis in 5-year-categories.
SIR = Standardized incidence ratio, CI = Confidence Interval, CBC = contralateral breast cancer, ER = Estrogen receptor.
doi:10.1371/journal.pone.0046535.t003
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ER-positive CBC; no effect is seen for the risk of ER-negative
CBC.
Strengths of this study include that it was conducted in a
country with a unified healthcare system and a population-based
cancer register, which enabled close to complete case identifica-
tion. We reduced the risk of misclassification of CBC through
exclusion of women diagnosed with a previous cancer other than
breast cancer, women diagnosed with an initial TNM stage IV
breast cancer and women diagnosed with distant metastasis prior
to the second cancer, this strict definition is a potential explanation
for the somewhat lower incidence (454 cases per 100 000 person
years) shown in this study, compared to other studies
[1,2,3,4,5,6,7]. Among the limitations is the lack information on
HER2-status, since it was not been measured during the majority
of the study period. Further, due to a high degree of missing
information in the register we chose to not include progesterone
receptor (PR) status in the analysis. However, considering the
stronger endocrine therapy response prediction conferred by ER-
status and the high concordance between PR-status and ER-status
we believe that the loss information by not including PR-status is
not significant. Further, misclassification of ER-status cannot be
excluded since the measurements were preformed with different
methods. However, this misclassification of ER in relation
outcome status, if at all present, ought to be non-differential (as
there is no reason to believe that the misclassification of ER-
assessment of the second cancer would be dependent on the ER-
status of the first cancer) and would as such bias our results
towards the null.
We found breast cancer patients to have approximately doubled
risk of CBC, compared to the risk of breast cancer in the general
female population, and found no significant difference in relative
risk of CBC by ER-status of the first cancer (Table 2). ER-status of
the first cancer can thus not be used clinically for predicting the
risk of CBC (Table 2 and Figure 1A). However, the relative risk of
the two ER subtypes of CBC is quite different depending on the
ER-status of the first cancer; the risk of ER-positive CBC is higher
if the first cancer is ER-positive, and the risk for ER-negative CBC
is substantially increased if the first cancer was ER-negative
(Table 3 and Figure 1B). This may however primarily be seen as a
sign of the previously shown high concordance of ER-status in
CBC tumors [12,17,34,35] and is not currently of clinical
importance.
The findings in Table 3 indicate that an ER-positive first breast
cancer is a marker of increased risk of CBC in general, while an
ER-negative first breast cancer specifically increases the risk for
ER-negative CBC. This might imply that the underlying host
factors (environmental or genetic) causing ER-negative breast
cancer are relatively stronger compared to the host factors causing
ER-positive breast cancer. Despite extensive studies of potential
host factors (primarily genetic factors) increasing the risk of ER-
negative breast cancer specifically, while being less important for
ER-positive breast cancer, only one such factor of significance has
been found; BRCA-1 [36] (but there are indications that certain
single nucleotide polymorphisms are more important for ER-
negative breast cancer, this was recently shown also for CBC [37]).
On the other hand, several life style risk factors e.g; nulliparity and
late childbearing have been shown to increase the risk of ER-
positive breast cancer but do not seem to affect the risk of ER-
negative breast cancer [38,39,40]. Unknown risk factors could thus
be the reason for the higher incidence of ER-negative CBC
following ER-negative first cancer, we believe that there is a need
for studies elucidating this.
The two previous studies that have investigated the SIR of CBC
using unilateral breast cancer as the background population have
conflicting results. Bouchardy et al. [41] showed, in a small study
of 63 CBC-patients, no increased risk of CBC overall among
breast cancer patients compared to the risk of breast cancer in the
Table 4. Standardized incidence ratios (SIR) comparing the incidence of CBC to the incidence of unilateral breast cancer, for CBC








cases N SIR 95% CI
All CBC*
Hormone therapy treated ER-positive first cancer 7711 38 365 156 89.86 1.74 1.47–2.03
Non-hormone therapy treated ER-positive first cancer 835 6 214 37 13.15 2.81 1.98–3.87
ER-positive CBC
Hormone therapy treated ER-positive first cancer 7711 38 365 87 56.88 1.53 1.23–1.87
Non-hormone therapy treated ER-positive first cancer 835 6 214 22 7.26 2.80 1.75–4.23
ER-negative CBC
Hormone therapy treated ER-positive first cancer 7711 38 365 26 13.03 2.00 1.30–2.92
Non-hormone therapy treated ER-positive first cancer 835 6 214 3 2.00 1.51 0.31–4.41
*ER-status of the second cancer was unknown for 29% of the CBC-patients.
The cohort is restricted to patients diagnosed after 1990, since hormone therapy is not recorded in the register before then. SIR calculations were stratified on hormone
therapy treatment for first breast cancer and adjusted for age at first breast cancer in 5-year-categories and for period of first breast cancer in 10-year-categories.
SIR = Standardized incidence rate, CI = Confidence Interval, CBC = contralateral breast cancer, ER = Estrogen receptor.
doi:10.1371/journal.pone.0046535.t004
Table 5. Number of women at risk of CBC by year after
diagnosis, subdivided on ER-status of the first cancer.
Number of women at risk
ER-status of first cancer Year of follow-up
0 5 10 15 20
ER-positive 14 525 3 436 2 280 1 222 901
ER-negative 4 090 783 535 364 358
doi:10.1371/journal.pone.0046535.t005
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general female population. This finding is rather unexpected, in
contrast to the well-established high risk of yet another breast
cancer for breast cancer patients, and thereby potentially puts into
question the validity of the results. Kurian et al [21] assessed
hormone receptor status rather than ER and progesterone
receptor (PR) separately; hormone receptor-positive was defined
as ER- and/or PR-positive. They showed, in consistency with our
results, that patients with hormone receptor-positive first breast
cancer have approximately twice the risk of CBC compared to the
risk of breast cancer in the general female population, and the
relative risk increase was independent of ER-status of the second
cancer. However, Kurian et al. also showed a more than three-fold
risk of CBC if the first cancer was ER-negative, which was driven
by the almost 10 times increased relative risk of ER-negative CBC
for patients with ER-negative first cancer. Kurian et al found that
women who were young at diagnosis and women belonging to
ethnic groups other than non-Hispanic whites had the highest
relative risks of ER-negative CBC following an ER-negative first
cancer, this could potentially explain the discrepancy between that
study and ours, since both these groups are significantly more
frequent in the study by Kurian et al.
As previously shown [42,43,44] we note that the incidence of
CBC is higher among patients diagnosed with the first cancer at an
early age; the overall risk increase for breast cancer patients
compared to the general female population is two-fold, but for
women diagnosed before the age of 50 it is close to 6-fold (IRR:
5.73[95% CI: 4.86–6.72]) (Table 2). In contrast to the previous
studies of the effect of age at first diagnosis, we had the possibility
to separate the effect between ER-positive and ER-negative cancer
(Table 3). The effect seems to be more apparent for the ER-
negative cancers; in the young cohort the risk of ER-negative CBC
is more increased than the risk of ER-positive CBC. A tentative
explanation for this finding would be that both ER-negativity and
young age at diagnosis implies a relatively stronger genetic
(compared to the environmental) influence on the risk of breast
cancer, that these two factors coincide further increase the
probability of a genetic makeup rendering the woman susceptible
for (yet another) breast cancer.
We found the incidence of CBC overall to decrease over
calendar period, as both our group and others have shown
previously [45,46], a finding that is most likely due to the
widespread use of adjuvant chemo- and endocrine therapy in the
later decades, which markedly decrease the risk of CBC [9]. While
there, for chemotherapy, exists neither epidemiological evidence
nor any biological mechanism to suggest that the effect would be
different for ER-positive and ER-negative cancers, this is not the
case for endocrine therapy, which we therefore investigated
further. The effect size of endocrine therapy in our study is in the
same order as the effect size shown in a meta analysis of
randomized clinical trials (SIR for treated: 1.74 [95% CI: 1.47–
2.03] vs. SIR for untreated: 2.81 [95% CI: 1.98–3.87]) [9]. The
risk decrease is further enhanced when investigating the risk for
ER-positive CBC and not present for ER-negative CBC, which is
in accordance with the biological mechanism for endocrine
therapy. In contrast to the findings by Li et al [23,47], we found
no statistically significant increase of the risk of ER-negative CBC
for women treated, compared to not treated, by endocrine
therapy, but due to low number of ER-negative CBC among non-
treated women further confirmation might be needed.
In conclusion; the increased risk of CBC for breast cancer
patients compared to the risk of breast cancer for the general
female population is not dependent on ER-status of the first
cancer, which can thus not be used for risk prediction. However, it
seems that ER-positive breast cancer predicts an increased risk for
CBC in general while an ER-negative first cancer specifically
increases the risk for ER-negative CBC. This, in combination with
our finding that the increased risk compared to the general
population is further enhanced for young women and in particular
for ER-negative CBC, might imply effects of host factors that are
yet unknown. Finally, the protective effect of adjuvant endocrine
therapy for the first breast cancer is exclusively seen for the risk of
ER-positive CBC, however also these treated women have a
significantly higher risk of CBC than the risk of breast cancer for
general female population.
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